Phytoestrogens and osteoporosis of middle-aged and elderly women

doi:10.7504/fk2014040104

Abstract

Abstract:

Abstract: Results of most of the randomized controlled trials suggest that phytoestrogens may increase lumbar spine bone mineral density of middle-aged and elderly women,and reduce the level of urinary DPD,a bone resorptive indicator,thus reducing the risk of fractures of women. However,there is not enough evidence to recommend phytoestrogen as a standard treatment for osteoporosis in middle-aged and elderly women,but it would be used as an alternative for individualized therapy.

Key words: phytoestrogens, middle-aged and elderly women, osteoporosis, bone turnover markers, bone mineral density

摘要：

大多数的临床试验结果提示植物雌激素可以增加中老年女性腰椎骨密度，降低骨吸收指标尿脱氧吡啶啉（urine deoxypyridinoline，DPD）水平，从而降低中老年女性骨折的风险。但是，现有的研究证据还不足以推荐植物雌激素作为治疗中老年女性骨质疏松症的标准方案，仅可作为个体化治疗的一种有益的选择。

关键词: 植物雌激素, 中老年女性, 骨质疏松症, 骨转换指标, 骨密度

CLC Number:

R711

ZOU Shi-En,ZHANG Shao-Fen. Phytoestrogens and osteoporosis of middle-aged and elderly women[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2014040104.

邹世恩，张绍芬. 植物雌激素与中老年女性骨质疏松症[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2014040104.

References

[1］ Piláková L,Riecansky I,Jagla F. The physiological actions of isoflavone phytoestrogens［J］. Physiol Res,2010,59(5):651-664.

[2］ Patisaul HB,Jefferson W. The pros and cons of phytoestrogens［J］. Front Neuroendocrinol,2010,31(4):400-419.

[3］ Mortensen A,Kulling SE,Schwartz H,et al. Analytical and compositional aspects of isoflavones in food and their biological effects［J］. Mol Nutr Food Res,2009,Suppl 2:S266-S309.

[4］ Cederroth CR,Nef S. Soy,phytoestrogens and metabolism: A review［J］. Mol Cell Endocrinol,2009,304(1-2):30-42.

[5］ Setchell KD,Brown NM,Desai PB,et al. Bioavailability,disposition,and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes［J］. J Nutr,2003,133(4):1027-1035.

[6］ Setchell KD,Clerici C. Equol: history,chemistry,and formation［J］.J Nutr,2010,140(7):1355S-1362S

[7］ Taku K,Melby MK,Nishi N,et al. Soy isoflavones for osteoporosis: an evidence-based approach［J］. Maturitas,2011,70(4):333-338.

[8］ Taku K,Melby MK,Kurzer MS,et al. Effects of soyisoflavone supplements on bone turnover markers in menopausal women:systematic review and meta-analysis of randomized controlled trials［J］. Bone,2010,47(2):413-423.

[9］ Ma DF,Qin LQ,Wang PY,et al. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials［J］. Eur J ClinNutr,2008,62(2):155-161.

[10］ Wei P,Liu M,Chen Y,et al.Systematic review of soy isoflavone supplements on osteoporosis in women［J］. Asian Pac J Trop Med,2012,5(3):243-248.

[11］ Nishizawa Y,Nakamura T,Ohta H,et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)［J］. J Bone Miner Metab,2005,23(2):97-104.

[12］ Liu J,Ho SC,Su YX,et al. Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials［J］. Bone,2009,44(5):948-953.

[13］ Ma DF,Qin LQ,Wang PY,et al. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomizedcontrolled trials［J］. Clin Nutr,2008,27(1):57-64.

[14］ Taku K,Melby MK,Takebayashi J,et al. Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials［J］. Asia Pac J ClinNutr,2010,19(1):33-42. 

[15］ Tousen Y,Ezaki J,Fujii Y,et al. Natural S-equol decreases bone resorption in postmenopausal,non-equol-producing Japanese women: a pilot randomized,placebo-controlled trial［J］. Menopause,2011,18(5):563-574.

[16］ Castelo-Branco C,Soveral I. Phytoestrogens and bone health at different reproductive stages［J］. Gynecol Endocrinol,2013,29(8):735-743.

[17］ Zhang X,Shu XO,Li H,et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women［J］. Arch Intern Med,2005,165(16):1890-1895.

[18］ Koh WP,Wu AH,Wang R,et al. Gender-specific associations between soy and risk of hip fracture in the Singapore Chinese Health Study［J］. Am J Epidemiol,2009,170(7):901-909.

[19］ Tang X,Zhu X,Liu S,et al. Isoflavones suppress cyclic adenosine 3',5'-mono -phosphate regulatory element-mediated transcription in osteoblastic cell line［J］. J Nutr Biochem,2011,22(9):865-873.

[20］ Islander U,Jochems C,Lagerquist MK,et al. Estrogens in rheumatoid arthritis; the immune system and bone［J］. Mol Cell Endocrinol,2011,335(1):14-29.

[21］ Lampe JW. Is equol the key to the efficacy of soy foods?［J］.Am J Clin Nutr,2009,89(5):1664S-1667S.

[22］ Shanle EK,Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action［J］. Chem Res Toxicol,2011,24(1):6-19.

[23］ Hwang CS,Kwak HS,Lim HJ,et al. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist orantagonist depending on the estrogen concentration［J］. J Steroid Biochem Mol Biol,2006,101(4-5):246-253.

[24］ Chen AC,Donovan SM. Genistein at a concentration present in soy infant formula inhibits Caco-2BBe cell proliferation by causing G2/M cell cycle arrest［J］. J Nutr,2004,134(6):1303-1308.

[25］邹世恩,张绍芬,张锐,等.雌激素受体和过氧化物酶增殖子激活受体憬徊娑曰岸源蠖管赵潜；さ淖饔茫跩］. 中华医学杂志,2009,89(42):2972-2975.

[26］ Manas ES,Xu ZB,Unwalla RJ,et al. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods［J］. Structure,2004,12(12):2197-2207.

[27］ Routledge EJ,White R,Parker MG,et al. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta［J］. J Biol Chem,2000,275(46):35986-35993.

[28］ Crusodé de Souza M,Sasso-Cerri E,Cerri PS. Immunohistochemical detection of estrogen receptor beta in alveolar bone cells of estradiol-treated female rats: possible direct action of estrogen on osteoclast life span［J］.J Anat,2009,215(6):673-681.

[29］ Galea GL,Meakin LB,Sugiyama T,et al. Estrogen receptor ? mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain,but their acute down-regulation of the Wnt antagonist Sost is mediated byestrogen receptor 猓跩］. J Biol Chem,2013,288(13):9035-9048.

[30］ Okazaki R,Inoue D,Shibata M,et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation inmouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta［J］. Endocrinology,2002,143(6):2349-2356.

[31］ Somjen D,Katzburg S,Sharon O,et al. Sex specific response of cultured human bone cells to ER? and ER? specific agonists by modulation of cell proliferation and creatine kinase specific activity［J］. J Steroid Biochem Mol Biol,2011,125(3-5):226-230.

[32］ Bradford PG,Gerace KV,Roland RL,et al. Estrogen regulation of apoptosis in osteoblasts［J］. Physiol Behav,2010,99(2):181-185.

[33］邹世恩,张绍芬. 异黄酮防治绝经后骨质疏松症分子学机制的研究进展［J］. 中国骨质疏松杂志,2007,13(5):364-366.

[34］ Wright HL,McCarthy HS,Middleton J,et al. RANK,RANKL and osteoprotegerin in bone biology and disease［J］. Curr Rev Musculoskelet Med,2009,2(1):56-64.

[35］ Kong YY,Boyle WJ,Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology［J］. Immunol Today,2000,21(10):495-502.

[36］ Marini H,Minutoli L,Polito F,et al. OPG and sRANKL serum concentrations in osteopenic,postmenopausal women after 2-yeargenistein administration［J］. J Bone Miner Res,2008,23(5):715-720.

[1]	PENG Hong-fa，YAN Xiao-nan. Menopausal hormone therapy and osteoporosis. [J]. Acta Metallurgica Sinica, 2020, 36(3): 230-233.
[2]	LEI Xiao-min，TAN Xin-sha. Effects of premature ovarian insufficiency on bone metabolism [J]. Acta Metallurgica Sinica, 2018, 34(3): 245-248.
[3]	. 原发性骨质疏松的共同特点为在骨代谢过程中,骨吸收和骨形成之间出现失衡，病因复杂，发病机制与遗传、内分泌紊乱、营养不均衡和废用等有关。现综述如下。 1 遗传因素家系和双胞胎研究表明骨质疏松有很强的遗传倾向。遗传因素在骨量和骨强度的获得上起重要作用。基因的多态性与骨代谢的差异有着密切的关系，并且是由多个候选基因而非单一基因共同影响的。近年来有关基因研究较多并得到人们关注的候选基因主要有维生素D受体(vitamin D receptor,VDR)基因、雌激素受体(estrogen receptor,ER)基因、Ⅰ型胶原基因及一些生长因子基因。 1. [J]. Acta Metallurgica Sinica, 2014, 30(5): 379-382.
[4]	YU Qi. More attention should be paid to menopause related osteoporosis. YU Qi [J]. Acta Metallurgica Sinica, 2014, 30(5): 321-322.
[5]	JIANG Jian-fa,SUN Ai-jun. Epidemiology,classification and diagnosis of osteoporosis in middle-aged women [J]. Acta Metallurgica Sinica, 2014, 30(5): 323-326.
[6]	XU Ling. Menopausal hormone therapy and osteoporosis in midlife and postmenopausal women [J]. Acta Metallurgica Sinica, 2014, 30(5): 333-336.
[7]	HUANG Qi-ren. Calcium,Vitamin D and osteoporosis [J]. Acta Metallurgica Sinica, 2014, 30(5): 336-340.
[8]	TAN Yong. TCM prevention and treatment strategies of middle-aged women with osteoporosisTCM prevention and treatment strategies of middle-aged women with osteoporosis [J]. Acta Metallurgica Sinica, 2014, 30(5): 340-343.
[9]	ZOU Jun. Exercise in the treatment and prevention of osteoporosis in elderly women [J]. Acta Metallurgica Sinica, 2014, 30(5): 343-347.
[10]	MA Ying. The other treatments for osteoporosis in middle-aged and elderly women [J]. Acta Metallurgica Sinica, 2014, 30(5): 347-351.
[11]	. [J]. Acta Metallurgica Sinica, 2014, 30(5): 379-382.
[12]	. [J]. Acta Metallurgica Sinica, 2014, 30(5): 383-386.
[13]	. Study of bone mineral density in complete androgen insensitivity syndrome: estrogen alone or estrogen with bisphosphonates treatment after orchiectomy. [J]. , 2012, 28(12): 915-917.